Methods	Six-week randomised, double-blind study.
Participants	Outpatients fulfilling DSM-III criteria for unipolar major depression (single or recurrent), with the present episode lasting 4 weeks or more and with a score of at least 20 on the HDRS-21. Age range: over 62 years old. Exclusion criteria: serious medical illness, unstable cardiac arrythmias, seizure disorders, history of allergy to either drug, severe psychosis, suicidal symptoms or DSM-II diagnosis of schizophrenia, bipolar disorder, organic mental disorder, substance abuse disorder within the past year or paranoid disorders, use of either drugs within 1 month preceeding study entry, MAOI in the prior 14 days or other antidepressants at the time of entry
Interventions	Fluoxetine: 14 participants. Trazodone: 13 participants. Fluoxetine dose range: 20-60 mg/day. Trazodone dose range: 50-400 mg/day. Only use of benzodiazepines and chloral hydrate for sleep were allowed
Outcomes	Hamilton Rating Scale for Depression (HDRS-21), CGI, TESS.
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear